Search
Now showing items 1-4 of 4
The design and evaluation of an l-dopa-lazabemide prodrug for the treatment of Parkinson’s disease
(MDPI, 2017)
l-Dopa, the metabolic precursor of dopamine, is the treatment of choice for the symptomatic relief of the advanced stages of Parkinson’s disease. The oral bioavailability of l-dopa, however, is only about 10% to 30%, and ...
The monoamine oxidase inhibition properties of selected structural analogues of methylene blue
(Elsevier, 2017)
The thionine dye, methylene blue (MB), is a potent inhibitor of monoamine oxidase (MAO) A, a property that may, at least in part, mediate its antidepressant effects in humans and animals. The central inhibition of MAO-A ...
C6- and C7-substituted 3,4-dihydro-2(1H)-quinolinones as inhibitors of monoamine oxidase
(Thieme, 2017)
Purpose Monoamine oxidase (MAO) inhibitors are considered to be useful therapeutic agents and isoform specific inhibitors are employed for the treatment of depression and Parkinson’s disease. MAO inhibitors are also under ...
The evaluation of 1,4-benzoquinones as inhibitors of human monoamine oxidase
(Elsevier, 2017)
The monoamine oxidase (MAO) enzymes are of considerable pharmacological interest and inhibitors are used in the clinic for the treatment of major depressive disorder and Parkinson's disease. A limited number of studies ...